Graft Versus Host Disease Battle – 12.27.2017 – Ivanhoe
Stem cell transplants can be the best hope for a cure from diseases like leukemia. Too often, rejection, or graft versus host disease (GVHD) follows, and it can be deadlier than the original disease. A researcher in Seattle is encouraged by a new combination of therapies that may prevent GVHD altogether. Childhood cancer researcher Dr. Leslie Kean, associate director, Ben Towne Center for Childhood Cancer Research, Seattle Children’s Research Institute has worked her entire career to find something to prevent GVHD.
The future of immunotherapy treatment for pediatric cancers – 1.31.2018 – Children’s Hospitals Today
Over the last several years, immunotherapy has emerged as a promising alternative to traditional forms of cancer treatment. Seattle Children's Hospital is at the forefront of these efforts, with several trials underway to better treat leukemia in children and young adults by boosting the immune system with T-cell immunotherapy. Researchers hope T-cell therapy will transform care for some childhood cancers, making treatment more effective, in less time and with milder side effects. Children's Hospitals Today caught up with Dr. Michael Jensen, director of the Ben Towne Center for Childhood Cancer Research at Seattle Children's, to gather his perspectives on the future of immunotherapy treatment for pediatric cancers.
In the future, cancer treatment may be remote controlled – 2.6.2018 – Healthline
In the future, fighting cancer may no longer mean grueling chemotherapy, but genetically altered immune systems that can be “remote controlled.” That’s currently the hope of researchers based at the University of California, San Diego, who are investigating if ultrasound waves can manipulate immune system T cells to effectively create a new form of cancer treatment. Dr. Rebecca Gardner, an oncologist at Seattle Children’s Hospital, said this study is a “pretty nifty idea.” “What’s really unique about this study is that it’s anatomically specific,” said Gardner, who’s also a principal investigator of two CAR T-cell immunotherapy clinical trials at Seattle Children’s. “You have to have the ultrasound machine that goes to where the CAR T cells are and turns them on only in that location.”